Serum miR-632 is a potential marker for the diagnosis and prognosis in laryngeal squamous cell carcinoma.

It has been demonstrated that miRNAs play critical roles in the tumorigenesis and progression of various tumors. The purpose of this research was to determine the serum miR-632 levels in patients with laryngeal squamous cell carcinoma (LSCC) and to investigate its diagnostic and prognostic value. We detected serum miR-632 levels in 162 LSCC patients and 42 healthy volunteers. The ROC curve was carried out to determine diagnostic accuracy. We observed that serum miR-632 levels were upregulated in LSCC patients compared with healthy volunteers ( < .01). Subsequent results from ROC indicated that high sensitivity and specificity of serum miR-632 for diagnosing LSCC (area under the curve 0.8828). In addition, it was found that high expressions of serum miR-632 were significantly associated with advanced N stage ( = .020), histological grade ( = .001), and TNM stage ( = .014). Furthermore, patients with higher serum miR-632 expression had a shorter OS and DFS time than those with lower serum miR-632 levels. Our data revealed that serum miR-632 may be a potential noninvasive biomarker which may become a potential diagnostic and prognostic biomarker for LSCC patients.